Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease

被引：3
|
作者：
Kim, Bo-Guen [1 ]
Kim, Sae Rom [2 ]
Jhun, Byung Woo [3 ]
机构：
[1] Hanyang Univ, Coll Med, Dept Internal Med, Div Pulm Med & Allergy, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Pulm & Crit Care Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, 81 Irwon Ro, Seoul 06351, South Korea
来源：
TUBERCULOSIS AND RESPIRATORY DISEASES | 2024年 / 87卷 / 02期
关键词：
LUNG-DISEASE;
D O I：
10.4046/trd.2023.0120
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：202 / 205
页数：4
相关论文
共 50 条
  • [31] Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
    Kim, Bo-Guen
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Baek, Sun-Young
    Sohn, Insuk
    Jhun, Byung Woo
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) : 1 - 12
  • [32] Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease A 12-Month Open-Label Extension Clinical Trial
    Winthrop, Kevin L.
    Flume, Patrick A.
    Thomson, Rachel
    Mange, Kevin C.
    Yuen, Dayton W.
    Ciesielska, Monika
    Morimoto, Kozo
    Ruoss, Stephen J.
    Codecasa, Luigi R.
    Yim, Jae-Joon
    Marras, Theodore K.
    van Ingen, Jakko
    Wallace, Richard J., Jr.
    Brown-Elliott, Barbara A.
    Coulter, Chris
    Griffith, David E.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (07) : 1147 - 1157
  • [33] Amikacin liposome and Mycobacterium avium complex: A systematic review
    Zangiabadian, Moein
    Malekshahian, Donya
    Arabpour, Erfan
    Abadi, Sahel Shafiee Dolat
    Yazarlou, Fartous
    Bostanghadiri, Narjess
    Centis, Rosella
    Aghababa, AmirHossein Akbari
    Farahbakhsh, Mohammad
    Nasiri, Mohammad Javad
    Sotgiu, Giovanni
    Migliori, Giovanni Battista
    PLOS ONE, 2022, 17 (12):
  • [34] ALIS (Amikacin Liposome Inhalation Suspension) for the Treatment of Patients with Refractory Mycobacterium avium Complex Lung Disease (MACLD) the Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
    Marras, T. K.
    Hassan, M.
    Mange, K. C.
    Ciesielska, M.
    Sonnenahalli, S. Dhar
    Jumadilova, Z.
    Chatterjee, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [35] RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
    Griffith, David
    Eagle, Gina
    Wallace, Richard
    Brown-Elliott, Barbara
    Van Ingen, Jakko
    Pennings, Lian
    Berry, Brooke
    Pandey, Sushil
    Coulter, Christopher
    Syrmis, Melanie
    Morimoto, Kozo
    Hasegawa, Naoki
    CHEST, 2018, 154 (04) : 109A - 110A
  • [36] A Retrospective Analysis to Assess the Effect of Targeted Clinical Interventions on the Discontinuation Rate of Amikacin Liposome Inhalation Suspension Therapy Among Patients Treated for Refractory Mycobacterium Avium Complex Lung Disease
    Hebble, S.
    Puc, M.
    Koerner, P.
    Barry, B.
    Faris, R.
    Vanscoy, G. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [37] Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients
    Griffith, D. E.
    Eagle, G.
    Thomson, R. M.
    Aksamit, T. R.
    Hasegawa, N.
    Morimoto, K.
    Addrizzo-Harris, D. J.
    O'Donnell, A. E.
    Marras, T. K.
    Flume, P. A.
    Loebinger, M. R.
    Morgan, L. C.
    Castellotti, P. F.
    Hill, A. T.
    Ruoss, S. J.
    Yim, J. J.
    Ringshausen, F. C.
    Field, S. K.
    Nezamis, J.
    Winthrop, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [38] Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex Lung Disease (MAC-LD) in the CONVERT Study
    Griffith, D. E.
    Thomson, R.
    Addrizzo-Harris, D. J.
    Field, S. K.
    van Ingen, J.
    Wallace, R. J., Jr.
    Coulter, C.
    Mange, K.
    Nezamis, J.
    Winthrop, K. L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [39] The treatment outcomes of cavitary Mycobacterium avium complex pulmonary disease according to the use of amikacin or streptomycin
    Kim, Seong Min
    Shim, Tae Sun
    Jo, Kyung-Wook
    RESPIROLOGY, 2023, 28 : 204 - 204
  • [40] Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
    Kim, Seong Min
    Chong, Yong Pil
    Lee, Hyun Joo
    Shim, Tae Sun
    Jo, Kyung-Wook
    MICROBIOLOGY SPECTRUM, 2023, 11 (03)
12345